James Mullen

Billionaire activist investor Carl Icahn announced that he will attempt to sell Biogen Idec Inc (Nasdaq: BIIB). Icahn Partners LP and its affiliates own 16.1 million shares, or 6% of outstanding shares, of Biogen Idec. Icahn has had a series of proxy battles with Biogen Idec and the company...

Standpoint Research initiated coverage on Biogen Idec Inc. (NASDAQ: BIIB) with a Buy recommendation and a 12 month price target of $70. James C. Mullen, CEO of Biogen Idec said that the company's business strategy is centered on the following areas: Accelerating the growth of TYSABRI; Extending...

Biogen Idec Inc. (NASDAQ: BIIB) has announced submission of a marketing authorization application (MAA) to the European Medicines Agency for its Fampridine Prolonged Release tablets. The oral therapy improves walking ability in adult patients with multiple sclerosis. Biogen Idec Inc. has also...